iTonic Regains Nasdaq Compliance After 10 Days of Closing Above $1
Key Facts
iTonic Holdings regained compliance with Nasdaq’s minimum bid price requirement after the closing bid price for its Class A shares was at least $1.00 per share for 10 consecutive business days from October 6 to 19, 2026. Nasdaq confirmed to the company that it had regained compliance and closed the matter, according to an iTonic statement published on October 28. The company said it received written notice of the decision dated October 20, 2026. The notice closes a matter that began a year earlier, when the exchange warned of a price deficiency in October 2025. The decision concerns only the bid price requirement, according to the statement.
The issue began when Nasdaq notified the company on October 20, 2025, that it was below the minimum bid price. After the initial 180-calendar-day compliance period ended on April 20, 2026, the exchange granted the company an additional 180-day extension on April 21. Nasdaq set October 19, 2026, as the deadline to regain compliance. The company had said that failure to meet the requirement by that date would result in written delisting notice. The company could request a review by a Nasdaq hearings panel after receiving the notice, according to its earlier disclosure with the U.S. Securities and Exchange Commission.
The start of the 10-day period Nasdaq used coincided with the start of trading in Class A shares on a post-reverse-split basis on October 6, 2026. iTonic completed a 16-for-1 reverse stock split before the compliance period was counted. Under Nasdaq Rule 5550(a)(2), the minimum bid price for continued listing on the Nasdaq Capital Market is $1 per share. The exchange determined that the company met this requirement during the specified period. The decision closed the price-related matter, without by itself confirming that other listing requirements had been met.
iTonic describes itself as a healthcare company focused on digital medical technologies. It says its strategy includes investing and forming partnerships in artificial intelligence, automation and data platforms for medical applications. In its 2025 annual report, the company reported revenue of $523,031, compared with $448,196 in 2024 and $628,591 in 2023. It also reported a net loss of $5,098,384 in 2025. The company said its losses and negative operating cash flows raised substantial doubt about its ability to continue as a going concern.
In the same annual report, the company said disclosure controls were ineffective as of December 31, 2025, and management identified 3 material weaknesses in internal control over financial reporting. In a private financing disclosed for the first half of 2026, iTonic had issued 100,000,000 Class A shares at $0.20 per share through June 30, for total gross proceeds of $20,000,000. The shares began trading under the ticker ITOC on January 16, 2026, after the company changed its name and ticker. These disclosures place the compliance announcement within a broader company record that includes its financial and financing data. The current Nasdaq notice is limited to closing the minimum-price matter.
EL7’s available closing data showed ITOC closed at $3.23 on October 22, 2026, then at $2.80 on October 23 and $2.53 on October 26. The close rose to $2.65 on October 27, then to $3.00 on October 28. These prices cover sessions before the announcement published on October 28 and the session on which it was published. Closing data alone do not identify the cause of daily moves or establish that the price is stable. Nasdaq had confirmed compliance based on the October 6–19 period, before the close recorded on October 28.